Table 3.

Results of base-case analyses

	Vedolizumab	Conventional therapy	Difference
Mixed population
Costs	288,284	309,680	− 21,397
QALYs	9.92	9.00	0.92
ICER ($ per QALY gained)			Dominant
Anti-TNF-naïve population
Costs	264,301	297,785	− 33,484
QALYs	10.86	9.46	1.40
ICER ($ per QALY gained)			Dominant
Anti-TNF-failure population
Costs	303,551	316,627	− 13,076
QALYs	9.32	8.74	0.58
ICER ($ per QALY gained)			Dominant

ICER incremental cost-effectiveness ratio